Last reviewed · How we verify
Raltegravir (Use RAL as a simplification strategy)
Raltegravir (RAL) is an antiretroviral medication developed by Merck and used primarily for the treatment of HIV infection. It works by inhibiting the integrase enzyme, preventing the virus from integrating its genetic material into the host cell's DNA. RAL is part of the integrase inhibitors class and is typically used in combination with other antiretrovirals. Despite its efficacy, RAL has several side effects, including nausea, headache, and diarrhea. The drug is not approved by the FDA but is used in clinical settings, particularly at Hospital Carlos III in Madrid.
At a glance
| Generic name | Raltegravir (Use RAL as a simplification strategy) |
|---|---|
| Sponsor | Hospital Carlos III, Madrid |
| Drug class | Integrase inhibitors |
| Target | C-C chemokine receptor type 1, Gag-Pol polyprotein, Integrase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Human immunodeficiency virus infection
Pipeline indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: